Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Vaxcyte, Inc. (PCVX) had Normalized Pre-Tax Income of $-180.80M for the most recently reported fiscal quarter, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-180.80M |
|
-- |
|
-- |
|
$196.68M |
|
$-196.68M |
|
$15.88M |
|
$-180.80M |
|
|
Normalized Pre-Tax Income |
$-180.80M |
$-180.80M |
|
$-180.80M |
|
$-180.80M |
|
$-180.80M |
|
$-196.68M |
|
$-196.10M |
|
97.16M |
|
97.16M |
|
$-1.83 |
|
$-1.83 |
|
| Balance Sheet Financials | |
$1.10B |
|
$79.63M |
|
$311.96M |
|
$1.41B |
|
$145.34M |
|
-- |
|
$22.11M |
|
$167.45M |
|
$1.24B |
|
$1.24B |
|
$1.24B |
|
95.36M |
|
| Cash Flow Statement Financials | |
$-296.79M |
|
$-773.31M |
|
$639.81M |
|
$835.53M |
|
$398.55M |
|
$-436.97M |
|
$48.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-312.85M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.58% |
|
-14.58% |
|
-12.84% |
|
-14.58% |
|
$13.01 |
|
$-3.22 |
|
$-3.05 |
|